Скачать или смотреть New Data on Role of Gene Assays in Breast Cancer Treatment - Medpage Today

Patients with ultra-low-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, according to new analyses presented at the recent virtual American Society of Clinical Oncology (ASCO) annual meeting.

The MINDACT trial established the 70-gene signature's ability to risk-stratify patients by a tumor's genomic signature, while the NRG Oncology/NSABP B-42 trial evaluated the impact of the 70-gene signature on extended aromatase inhibitor (AI) therapy.

In this second of four exclusive episodes, MedPage Today brought together three expert leaders in the field. Moderator Hope S. Rugo, MD, of the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, is joined by Jennifer Litton, MD, of the University of Texas MD Anderson Cancer Center in Houston, and William J. Gradishar, MD, of Northwestern University Feinberg School of Medicine in Chicago, for a virtual roundtable discussion on the impact of these results.